{"denomUnitsSelected":"Participants","description":"Description, grade (per CTCAE v4.03), seriousness and relatedness","reportingStatus":"NOT_POSTED","timeFrame":"Upon study enrollment, then subsequently at the first visit of each cycle (cycle length is 21 days), at the time of any adverse event, through end of treatment study visit, assessed up to 36 months","title":"Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Pembrolizumab and Cetuximab, Graded According to NCI CTCAE v4.03","type":"SECONDARY"}